Overview

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified release (MR) 30 mg.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole
Proton Pump Inhibitors